Shumin Chen

Title: Shumin Chen: Innovator in Adverse Drug Reaction Detection

Introduction

Shumin Chen is a notable inventor based in Jinan, China. He has made significant contributions to the field of pharmacogenetics, particularly in the detection of adverse drug reactions. His work focuses on the HLA-B*1301 allele and its implications for patient safety.

Latest Patents

Shumin Chen holds a patent for the "Use of HLA-B*1301 allele." This invention discloses methods for detecting whether a person has the HLA-B*1301 allele. It is particularly relevant for evaluating the risk of adverse drug reactions in response to the medication dapsone. The patent outlines that individuals with the HLA-B*1301 allele are at a higher risk of experiencing adverse reactions when administered dapsone, especially those with the allele present on both chromosomes.

Career Highlights

Throughout his career, Shumin Chen has worked at esteemed institutions such as the Shandong Provincial Institute of Dermatology and Venereology. His research has been pivotal in advancing the understanding of genetic factors that influence drug reactions.

Collaborations

Shumin Chen has collaborated with notable colleagues, including Furen Zhang and Hong Liu. Their joint efforts have contributed to the advancement of research in dermatology and pharmacogenetics.

Conclusion

Shumin Chen's innovative work in the detection of adverse drug reactions highlights the importance of genetic testing in personalized medicine. His contributions continue to impact patient safety and treatment efficacy.